Drug Profile
Research programme: HDAC6 inhibitors - Kancera
Alternative Names: KAN-0440262Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Kancera
- Class Antineoplastics
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma; Neuropathic pain; Solid tumours
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for research development in Neuropathic-pain in Sweden
- 28 Jun 2022 No recent reports of development identified for preclinical development in Multiple-myeloma in Sweden (Parenteral)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Solid-tumours in Sweden (Parenteral)